miR-21, one of the most extensively studied oncomiRs, modulates the PTEN/AKT pathway in lung cancer by directly targeting PTEN’s 3′UTR, which leads to activation of the PI3K/AKT pathway and downstream effects on cell proliferation, resistance to apoptosis, metastasis, and resistance to immunotherapy [42,43]. This evidence concerns the gene AKT1 and lung carcinoma.